Review
doi: 10.1111/j.1742-1241.2006.01182.x.
Refractory neurogenic detrusor overactivity
Affiliations
- PMID: 17169007
- DOI: 10.1111/j.1742-1241.2006.01182.x
Item in Clipboard
Review
Refractory neurogenic detrusor overactivity
Int J Clin Pract Suppl.
2006 Dec.
Abstract
Refractory neurogenic detrusor overactivity refers to the clinical condition that is no longer manageable by anticholinergic therapy. This condition represents a formidable task to caregivers because the treatment of urinary incontinence and adequate protection of the upper urinary tract become extremely difficult. Treatment options for refractory neurogenic detrusor overactivity include detrusor injections of botulinum toxin and intravesical instillation of vanilloid compounds, mainly resiniferatoxin, or anticholinergic drugs. If these options fail, bladder augmentation or sacral anterior root stimulation offers excellent outcomes, although at much higher costs and risks to the patients.
Similar articles
-
Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.J Urol. 2004 Jul;172(1):240-3. doi: 10.1097/01.ju.0000132152.53532.5d. J Urol. 2004. PMID: 15201783 Clinical Trial.
-
Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.Urology. 2004 May;63(5):868-72. doi: 10.1016/j.urology.2003.12.007. Urology. 2004. PMID: 15134967
-
Botulinum toxin type A for neurogenic detrusor overactivity due to spinal cord lesions in children: a retrospective study of seven cases.J Pediatr Urol. 2009 Dec;5(6):430-6. doi: 10.1016/j.jpurol.2009.06.001. Epub 2009 Jul 3. J Pediatr Urol. 2009. PMID: 19577520
-
Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity.BJU Int. 2008 Jul 25;102 Suppl 1:7-10. doi: 10.1111/j.1464-410X.2008.07827.x. BJU Int. 2008. PMID: 18665972 Review.
-
Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?Curr Opin Urol. 2009 Jul;19(4):347-52. doi: 10.1097/MOU.0b013e32832ae176. Curr Opin Urol. 2009. PMID: 19444121 Review.
Cited by
-
Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB).Pharmaceuticals (Basel). 2023 Feb 28;16(3):372. doi: 10.3390/ph16030372. Pharmaceuticals (Basel). 2023. PMID: 36986471 Free PMC article.
-
Resiniferatoxin: Nature's Precision Medicine to Silence TRPV1-Positive Afferents.Int J Mol Sci. 2023 Oct 10;24(20):15042. doi: 10.3390/ijms242015042. Int J Mol Sci. 2023. PMID: 37894723 Free PMC article. Review.
-
The evaluation and management of refractory neurogenic overactive bladder.Curr Urol Rep. 2014 Oct;15(10):444. doi: 10.1007/s11934-014-0444-z. Curr Urol Rep. 2014. PMID: 25118853 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical